GRAHAM FARNHAM: Open Payments
NPI 1659822278 · BEACON, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,135 in 66 payments from 9 companies in 2025. Trend: 2023 $528 · 2024 $951 · 2025 $1,135
Food & beverage: $1,135
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $330 |
| ABBVIE INC. | 19 | $302 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $216 |
| Teva Pharmaceuticals USA, Inc. | 6 | $98 |
| Supernus Pharmaceuticals, Inc. | 4 | $59 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $50 |
| E.R. Squibb & Sons, L.L.C. | 3 | $47 |
| Lundbeck LLC | 1 | $18 |
| Bausch Health US, LLC | 1 | $17 |
Products named: VRAYLAR, CAPLYTA, REXULTI, ABILIFY MAINTENA, UZEDY, Qelbree, TRINTELLIX, COBENFY.
Industry payments across NY — which companies pay providers there.
